Baxter International BAX Pharmaceuticals — Currency translation and other
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments.
The official record: Baxter International’s 10-K, filed February 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Baxter International's pharmaceuticals — currency translation and other.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Baxter International's pharmaceuticals — currency translation and other?
- Baxter International (BAX) reported pharmaceuticals — currency translation and other of $9.25M in Q4 2025.
- How has Baxter International's pharmaceuticals — currency translation and other changed year-over-year?
- Baxter International's pharmaceuticals — currency translation and other increased by 260.9% year-over-year, from -$5.75M to $9.25M.
- What does pharmaceuticals — currency translation and other mean?
- The net financial impact of foreign currency exchange rate changes and miscellaneous adjustments on the segment's performance.
- How do you interpret pharmaceuticals — currency translation and other?
- An increase in negative values suggests adverse currency headwinds, while positive values indicate favorable exchange rate impacts or non-recurring gains.
- How does pharmaceuticals — currency translation and other compare across companies?
- Commonly reported by multinational healthcare companies as 'Foreign Exchange Impact' or 'Currency Effects' within segment reconciliations.